Jump to content
Objectivism Online Forum

Reblogged: Paul Hsieh Forbes Column: The Positive Value of Negative Dr

Rate this topic


Recommended Posts

My latest Forbes piece is now out: “The Positive Value of Negative Drug Trials“.

I discuss the unfortunate bias against publishing “negative” scientific results that show a drug doesn’t have much clinical benefit, and why it’s in the self-interest of drug companies to still report these.

In particular, I highlighted two interesting facts:

1) Most drug trial results are still not being reported to a central registry.

2) Negative results funded by private industry (e.g., pharmaceutical companies) are more likely to be reported than from government-funded research.

Fortunately, free market incentives are driving more drug companies towards full disclosure of both positive and negative study results — which will benefit patients.

For more details, read the full text of “The Positive Value of Negative Drug Trials“.

vGZIkZfrl64

Link to Original
Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
 Share

  • Recently Browsing   0 members

    • No registered users viewing this page.
×
×
  • Create New...